These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 30077739)

  • 1. Novel CIL-102 derivatives as potential therapeutic agents for docetaxel-resistant prostate cancer.
    Miller DR; Tzeng CC; Farmer T; Keller ET; Caplan S; Chen YS; Chen YL; Lin MF
    Cancer Lett; 2018 Nov; 436():96-108. PubMed ID: 30077739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration-resistant prostate cancer.
    Pilling A; Kim SH; Hwang C
    Prostate; 2022 Feb; 82(2):182-192. PubMed ID: 34672379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.
    Lin HM; Lee BY; Castillo L; Spielman C; Grogan J; Yeung NK; Kench JG; Stricker PD; Haynes AM; Centenera MM; Butler LM; Shreeve SM; Horvath LG; Daly RJ
    Prostate; 2018 Mar; 78(4):308-317. PubMed ID: 29314097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NPRL2 promotes docetaxel chemoresistance in castration resistant prostate cancer cells by regulating autophagy through the mTOR pathway.
    Luo S; Shao L; Chen Z; Hu D; Jiang L; Tang W
    Exp Cell Res; 2020 May; 390(2):111981. PubMed ID: 32234375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cdc20/p55 mediates the resistance to docetaxel in castration-resistant prostate cancer in a Bim-dependent manner.
    Wu F; Lin Y; Cui P; Li H; Zhang L; Sun Z; Huang S; Li S; Huang S; Zhao Q; Liu Q
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):999-1006. PubMed ID: 29605876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Codelivery of GRP78 siRNA and docetaxel via RGD-PEG-DSPE/DOPA/CaP nanoparticles for the treatment of castration-resistant prostate cancer.
    Zhang X; He Z; Xiang L; Li L; Zhang H; Lin F; Cao H
    Drug Des Devel Ther; 2019; 13():1357-1372. PubMed ID: 31118572
    [No Abstract]   [Full Text] [Related]  

  • 8. Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer.
    Park SE; Kim HG; Kim DE; Jung YJ; Kim Y; Jeong SY; Choi EK; Hwang JJ; Kim CS
    Invest New Drugs; 2018 Apr; 36(2):195-205. PubMed ID: 29110173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p66Shc protein through a redox mechanism enhances the progression of prostate cancer cells towards castration-resistance.
    Miller DR; Ingersoll MA; Chatterjee A; Baker B; Shrishrimal S; Kosmacek EA; Zhu Y; Cheng PW; Oberley-Deegan RE; Lin MF
    Free Radic Biol Med; 2019 Aug; 139():24-34. PubMed ID: 31100478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of 2-(5,6,7-Trifluoro-1
    Leblanc E; Ban F; Cavga AD; Lawn S; Huang CF; Mohan S; Chang MEK; Flory MR; Ghaidi F; Lingadahalli S; Chen G; Yu IPL; Morin H; Lallous N; Gleave ME; Mohammed H; Young RN; Rennie PS; Lack NA; Cherkasov A
    J Med Chem; 2021 Oct; 64(20):14968-14982. PubMed ID: 34661404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression.
    Komura K; Jeong SH; Hinohara K; Qu F; Wang X; Hiraki M; Azuma H; Lee GS; Kantoff PW; Sweeney CJ
    Proc Natl Acad Sci U S A; 2016 May; 113(22):6259-64. PubMed ID: 27185910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting NPRL2 to enhance the efficacy of Olaparib in castration-resistant prostate cancer.
    Chen X; Chen Z; Zheng B; Tang W
    Biochem Biophys Res Commun; 2019 Jan; 508(2):620-625. PubMed ID: 30522863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer.
    Nelius T; Martinez-Marin D; Hirsch J; Miller B; Rinard K; Lopez J; de Riese W; Filleur S
    Cell Death Dis; 2014 May; 5(5):e1210. PubMed ID: 24810046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer.
    Ku S; Lasorsa E; Adelaiye R; Ramakrishnan S; Ellis L; Pili R
    PLoS One; 2014; 9(7):e103680. PubMed ID: 25072314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABCB1-mediated docetaxel resistance reversed by erastin in prostate cancer.
    Chen F; Wu S; Kuang N; Zeng Y; Li M; Xu C
    FEBS J; 2024 Jul; 291(14):3249-3266. PubMed ID: 38712529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KIFC1 induces resistance to docetaxel and is associated with survival of patients with prostate cancer.
    Sekino Y; Oue N; Shigematsu Y; Ishikawa A; Sakamoto N; Sentani K; Teishima J; Matsubara A; Yasui W
    Urol Oncol; 2017 Jan; 35(1):31.e13-31.e20. PubMed ID: 27665358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer.
    Mout L; Moll JM; Chen M; de Morrée ES; de Ridder CMA; Gibson A; Stuurman D; Aghai A; Erkens-Schulze S; Mathijssen RHJ; Sparreboom A; de Wit R; Lolkema MP; van Weerden WM
    Br J Cancer; 2020 Dec; 123(12):1715-1719. PubMed ID: 32989230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells.
    Park HS; Hong SK; Oh MM; Yoon CY; Jeong SJ; Byun SS; Cheon J; Lee SE; Moon du G
    Anticancer Res; 2014 Jul; 34(7):3457-68. PubMed ID: 24982354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deubiquitinating enzyme USP33 restrains docetaxel-induced apoptosis via stabilising the phosphatase DUSP1 in prostate cancer.
    Guo F; Zhang C; Wang F; Zhang W; Shi X; Zhu Y; Fang Z; Yang B; Sun Y
    Cell Death Differ; 2020 Jun; 27(6):1938-1951. PubMed ID: 31857702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.